Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection

• Päätekijät: Stuart Cohen (Tekijä), Thomas Louie (Tekijä), Charles Berenson (Tekijä), Alpesh Amin (Tekijä), David Lombardi (Tekijä), Sissi Pham (Tekijä), Shirley Huang (Tekijä), Elaine Wang (Tekijä), Brooke Hasson (Tekijä), Barbara McGovern (Tekijä), Lisa Von Moltke (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Cambridge University Press, 2022-07-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background: The estimated economic cost of Clostridioides difficile infection (CDI) is $5.4 billion annually, primarily attributed to acute-care costs. We previously reported data from ECOSPOR III that SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing recur...